TCM has committed into innovation, as for the research and development of new therapeutic, and has been actively dedicating into the patent-layout and new drug development for a total solution to liver disease, including prevention-TCM-800B combined with ETV for hepatitis B; genetic detection- ctDNA platform; and treatment- PTX-9908 combined with TACE for liver cancer and PTD-9908 combined anti-PD-1 treatment. Currently, company’s main revenue comes from the sales in multiple medical products which included medicine, medical device, functional food, in addition; we also obtained the exclusive-distribution of the Philips ventilator in Taiwan. Further, TCM has well utilizes the established cross-strait medical channel and cooperates with China partners for product sale and numbers of specialty generics’ submission to expand the business territory. Looking ahead, TCM Biotech will become an international biotech company that continuously working in the R&D, manufacturing and marketing of new drug in prevention and treatment of liver disease with well utilize the advantage of channel, product feature, completion strength to bring in maximum revenue and profit as goal.